56663-74-2

Basic information

• Product Name: 3-CHLORO-2,2-DIMETHYL-BUT-3-ENOIC ACID METHYL ESTER
• Synonyms: 3-CHLORO-2,2-DIMETHYL-BUT-3-ENOIC ACID METHYL ESTER;3-Chloro-2,2-dimethyl-3-butenoic acid methyl ester;Methyl 2,2-dimethyl-3-chloro-3-butenoate;Methyl 3-chloro-2,2-dimethylbut-3-enoate;3-Butenoic acid, 3-chloro-2,2-diMethyl-, Methyl ester
• CAS NO: 56663-74-2
• Molecular Formula: C₇H₁₁ClO₂
• Molecular Weight: 162.61
• Product Categories: pharmacetical
• Mol File: 56663-74-2.mol

Chemical Properties

• Boiling Point: 184℃
• Flash Point: 70℃
• Appearance: /
• Density: 1.056
• CAS DataBase Reference: 3-CHLORO-2,2-DIMETHYL-BUT-3-ENOIC ACID METHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 3-CHLORO-2,2-DIMETHYL-BUT-3-ENOIC ACID METHYL ESTER(56663-74-2)
• EPA Substance Registry System: 3-CHLORO-2,2-DIMETHYL-BUT-3-ENOIC ACID METHYL ESTER(56663-74-2)

Safety Data

• Hazardous Substances Data: 56663-74-2(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
3-CHLORO-2,2-DIMETHYL-BUT-3-ENOIC ACID METHYL ESTER is used as an intermediate in the synthesis of pharmaceuticals for its ability to react with other chemicals to form new substances with potential therapeutic properties.
Used in Agrochemical Industry:
3-CHLORO-2,2-DIMETHYL-BUT-3-ENOIC ACID METHYL ESTER is used as a precursor in the production of agrochemicals, such as pesticides and herbicides, due to its reactivity and potential to form new compounds with pesticidal or herbicidal properties.
Used in Materials Science:
3-CHLORO-2,2-DIMETHYL-BUT-3-ENOIC ACID METHYL ESTER is used in the development of new materials and compounds in materials science, leveraging its reactivity to create substances with specific properties for various applications.
It is crucial to handle 3-CHLORO-2,2-DIMETHYL-BUT-3-ENOIC ACID METHYL ESTER with care and follow proper safety precautions during its use in these industries to ensure the safety of workers and the environment.

Upstream product

• 105-45-3 acetoacetic acid methyl ester 
• 38923-57-8 methyl 2,2-dimethyl-3-oxobutanoate 

Downstream Products

• 952665-09-7 methyl 4-(2-butyramido-5-nitrophenyl)-2,2-dimethylbut-3-ynoate 
• 952665-08-6 methyl 4-(2-amino-5-nitrophenyl)-2,2-dimethylbut-3-ynoate 
• 95924-34-8 2,2-dimethyl-3-butynoic acid methyl ester 
• 56663-75-3 2,2-dimethyl-3-chloro-3-butenoic acid 
• 52066-34-9 3,3-dimethyl-pent-4-yn-2-one 

Relevant articles and documents

Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS

Compounds of the present invention and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette ('ABC') transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator ('CFTR'). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.

Modulators of ATP-binding cassette transporters

Compounds of the present invention and pharmaceutically acceptable compositions thereof, are useful as modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator (“CFTR”). The present invention also relates to methods of treating ABC transporter mediated diseases using compounds of the present invention.